DDrare: Database of Drug Development for Rare Diseases

Pembrolizumab (DrugBank: Pembrolizumab)

2 diseases

ID	Disease name (Link within this page)	Number of trials
25	Progressive multifocal leukoencephalopathy	1
285	Fanconi anemia	1

25. Progressive multifocal leukoencephalopathy [ 23 clinical trials, 33 drugs, (DrugBank: 20 drugs), 7 drug target genes, 36 drug target pathways]

Searched query = "Progressive multifocal leukoencephalopathy", "PML", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 23 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04091932 (ClinicalTrials.gov)	August 20, 2019	15/9/2019	Treatment of PD-1 Inhibitor in AIDS-associated PML	The Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Progressive Multifocal Leukoencephalopathy (PML): A One-center, Single-arm and Prospective Study	Progressive Multifocal Leukoencephalopathy;AIDS	Drug: Pembrolizumab	First Affiliated Hospital of Zhejiang University	NULL	Recruiting	18 Years	65 Years	All	10	Phase 2	China

285. Fanconi anemia [ 56 clinical trials, 111 drugs, (DrugBank: 31 drugs), 30 drug target genes, 151 drug target pathways]

Searched query = "Fanconi anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 56 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04483544 (ClinicalTrials.gov)	August 10, 2020	20/7/2020	Pembrolizumab and Olaparib in Cervical Cancer Patients	Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway	Cervical Cancer;Cervical Carcinoma	Drug: pembrolizumab;Drug: olaparib	Baptist Health South Florida	Florida Department of Health;Merck Sharp & Dohme Corp.	Recruiting	18 Years	N/A	Female	48	Phase 2	United States